Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 0.00 |
|
|||||
| News | - |
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| QRXPF | OTCMarkets | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.0001 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.0001 |
| Trades | Volume | Avg Volume |
|---|---|---|
| 0 | 0.00 | - |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 0.0001 | USD |
Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 7.50k | 75.00M | - | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical QRXPF Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Year | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 5 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
Description
| QRxPharma Limited is a specialty pharmaceutical company and has been focused on the development and commercialisation of new treatments for pain management and abuse prevention products. The Company's Dual Opioid platform technology is a patented fixed-ratio combination of morphine and oxycodone provides effective analgesia with the potential to decrease clinically important opioid-related side effects, in particular respiratory depression. QRxPharma has four complementary pain management product formulations in late and early stage clinical development including: Moxduo IR, an immediate release oral capsule for acute pain; an abuse deterrent formulation of Moxduo IR, Moxduo CR, a controlled release oral tablet (with abuse deterrent and tamper resistant technologies) for chronic pain; and Moxduo/ IV, an intravenous formulation for moderate to severe hospital-based pain. On 14 August 2014 the Company announced that it is halting all further development work on the Moxduo portfolio of products. |
